Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676830 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312
A Phase 1 study, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02676830 is a Phase 1 study that has completed, run by Kowa Research Institute. The registered enrollment target is 13 participants.
The verdict
NCT02676830, a Phase 1 study, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to Evaluation of absorption, metabolism, and excretion of \[14C\]-K-312 and estimation of the absolute bioavailability of K-312 in healthy male subjects
Interventions
- DRUG K-312 100 mg
- DRUG K-312 100 ug C14 IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02676830
The ClinicalTrials.gov registry entry for NCT02676830 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which K-312 100 mg is the first listed.
NCT02676830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02676830 about?
NCT02676830 is a clinical study titled "Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312". The purpose of this study is to Evaluation of absorption, metabolism, and excretion of \[14C\]-K-312 and estimation of the absolute bioavailability of K-312 in healthy male subjects
What is the current status of trial NCT02676830?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2014-08. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02676830?
The interventions under investigation include: K-312 100 mg (DRUG), K-312 100 ug C14 IV (DRUG).
Who is sponsoring clinical trial NCT02676830?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.